Total Assets
Stockholders' Equity
Cash & Equivalents
Long-Term Debt
Revenue trend
Balance Sheet
Income Statement
Per Share & Cash Flow
Insider activity
SEC fundamentals · as filed in 10-K FY2025, period ended Dec 31, 2025 · updated Aug 29, 2026
as filed in 10-K FY2025, period ended Dec 31, 2025 · View filings on EDGAR ↗
In its FY2025 report, Terns Pharmaceuticals, Inc. reported total assets of $1.03B and stockholders' equity of $1.01B. Every figure below is taken directly from Terns Pharmaceuticals, Inc.'s SEC filings: each links to the source document on EDGAR.
as of Dec 31, 2025 · 10-K
10-K (annual) · period ended Dec 31, 2025
10-K (annual) · period ended Dec 31, 2025
| EPS (diluted) | $-1.03 | Earnings | source ↗ |
| EPS (basic) | $-1.03 | Earnings | source ↗ |
| Shares Outstanding | 115.4M | Entity | source ↗ |
| Cash from Operations | -$82.2M | Net | source ↗ |
| Cash from Financing | $743.5M | Net | source ↗ |
| Cash from Investing | -$298.0M | Net | source ↗ |
Form 4 open-market activity, last 180 days
No material restatements detected across 134annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail behind the counts above, plus MCP access for your own agents, across the whole SEC universe.
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.